CD274 and cervical carcinoma: By June 2022, there were 153 clinical trials involving pembrolizumab, atezolizumab, durvalumab, nivolumab, and other PD-1/PD-L1 monoclonal antibodies in cervical cancer, including 44 for pembrolizumab, 14 for nivolumab, 12 for camrelizumab, 16 for atezolizumab, and 11 for durvalumab (e-Table 1).